Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is a clinical-stage biopharmaceutical company specializing in neurodegenerative diseases, leveraging its proprietary technology platforms to develop innovative therapeutic and diagnostic products targeting misfolded proteins. The NLRP3 program and the promising results from the PD active immunotherapy ACI-7104.056, which has shown a 20x increase in antibodies against pathogenic variants of aSyn, significantly enhance the company’s potential for advancement and success in the market. Additionally, the adoption of safer delivery methods for monoclonal antibodies, as evidenced by historical successful treatments, aligns AC Immune's pipeline with current trends favoring efficacious and patient-friendly treatment solutions in the Alzheimer's disease landscape.

Bears say

AC Immune SA reported a net operating loss of CHF16.2 million for the quarter, indicating significant financial challenges. The company is exposed to numerous industry-specific risks, including the potential for unexpected clinical outcomes, regulatory uncertainties, and the complexities of navigating an increasingly competitive and price-sensitive market for its therapeutic and diagnostic products. These factors contribute to a negative outlook as the company continues to grapple with maintaining financial viability while pursuing its ambitious goals in the neurodegenerative disease sector.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jan 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.